Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Advances in Cancer Chemoprevention and Therapeutics
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Advances in Cancer Chemoprevention and Therapeutics

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 6878

Special Issue Editor

Prof. Dr. Shun-Fa Yang

E-Mail Website
Guest Editor
1. Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan
2. Department of Medical Research, Chung Shan Medical University Hospital, Taichung 40201, Taiwan
Interests: eye diseases; polymorphism; cancer prevention; cancer biomarker; oral cancer; cancer metastasis; matrix metalloproteinase
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Despite current advances in surgery and other treatment options, the fatality of some cancers has remained mostly unchanged. Studies have shown that phytochemicals have the capability to prevent carcinogenesis. Therefore, new active compounds responsible for the anti-cancer characteristics of dietary plants, and original active compounds exert novel function on anti-carcinogenesis, are important issues in cancer investigation. We invite the researchers to contribute original and review articles regarding the relationship between phytochemicals and cancers, including the discovery of novel anti-cancer phytochemicals and the novel signalling pathways, and signalling molecules of phytochemicals on cancer treatment. We are pleased to invite you to our Special Issue on “Advances in Cancer Chemoprevention and Therapeutics”. We look forward to receiving your contributions.

Prof. Dr. Shun-Fa Yang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • phytochemicals
  • cancer
  • chemoprevention
  • metastasis
  • apoptosis
  • therapeutic target
  • biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

15 pages, 4038 KiB  
Article
STAT3 Pathways Contribute to β-HCH Interference with Anticancer Tyrosine Kinase Inhibitors
by Sara Fiorini, Elisabetta Rubini, Monia Perugini, Fabio Altieri, Silvia Chichiarelli, Giorgia Meschiari, Giulia Arrighetti, John Vijgen, Pier Giorgio Natali, Marco Minacori and Margherita Eufemi
Int. J. Mol. Sci. 2024, 25(11), 6181; https://doi.org/10.3390/ijms25116181 - 4 Jun 2024
Viewed by 962
Abstract
Organochlorine pesticides (OCPs) are a class of environmentally persistent and bioaccumulative pollutants. Among these, β-hexachlorocyclohexane (β-HCH) is a byproduct of lindane synthesis, one of the most worldwide widespread pesticides. β-HCH cellular mechanisms inducing chemical carcinogenesis correspond to many of those inducing chemoresistance, in [...] Read more.
Organochlorine pesticides (OCPs) are a class of environmentally persistent and bioaccumulative pollutants. Among these, β-hexachlorocyclohexane (β-HCH) is a byproduct of lindane synthesis, one of the most worldwide widespread pesticides. β-HCH cellular mechanisms inducing chemical carcinogenesis correspond to many of those inducing chemoresistance, in particular, by the activation of signal transducer and activator of transcription 3 (STAT3) signaling pathways. For this purpose, four cell lines, representative of breast, lung, prostate, and hepatocellular cancers, were treated with β-HCH, specific tyrosine kinase inhibitors (TKIs), and a STAT3 inhibitor. All cell samples were analyzed by a viability assay, immunoblotting analysis, a wound-healing assay, and a colony formation assay. The results show that β-HCH reduces the efficacy of TKIs. The STAT3 protein, in this context, plays a central role. In fact, by inhibiting its activity, the efficacy of the anticancer drug is restored. Furthermore, this manuscript aimed to draw the attention of the scientific and socio-healthcare community to the issue of prolonged exposure to contaminants and their impact on drug efficacy. Full article
(This article belongs to the Special Issue Advances in Cancer Chemoprevention and Therapeutics)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research, Other

45 pages, 889 KiB  
Review
Colorectal Cancer Chemoprevention: A Dream Coming True?
by Martina Lepore Signorile, Valentina Grossi, Candida Fasano and Cristiano Simone
Int. J. Mol. Sci. 2023, 24(8), 7597; https://doi.org/10.3390/ijms24087597 - 20 Apr 2023
Cited by 8 | Viewed by 3806
Abstract
Colorectal cancer (CRC) is one of the deadliest forms of cancer worldwide. CRC development occurs mainly through the adenoma-carcinoma sequence, which can last decades, giving the opportunity for primary prevention and early detection. CRC prevention involves different approaches, ranging from fecal occult blood [...] Read more.
Colorectal cancer (CRC) is one of the deadliest forms of cancer worldwide. CRC development occurs mainly through the adenoma-carcinoma sequence, which can last decades, giving the opportunity for primary prevention and early detection. CRC prevention involves different approaches, ranging from fecal occult blood testing and colonoscopy screening to chemoprevention. In this review, we discuss the main findings gathered in the field of CRC chemoprevention, focusing on different target populations and on various precancerous lesions that can be used as efficacy evaluation endpoints for chemoprevention. The ideal chemopreventive agent should be well tolerated and easy to administer, with low side effects. Moreover, it should be readily available at a low cost. These properties are crucial because these compounds are meant to be used for a long time in populations with different CRC risk profiles. Several agents have been investigated so far, some of which are currently used in clinical practice. However, further investigation is needed to devise a comprehensive and effective chemoprevention strategy for CRC. Full article
(This article belongs to the Special Issue Advances in Cancer Chemoprevention and Therapeutics)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

19 pages, 8794 KiB  
Case Report
Li–Fraumeni Syndrome: Narrative Review Through a Case Report with Ten Years of Primary Tumor Remission Associated with Sechium H387 07 Supplementation
by Angel Iván Amador-Gómez, Itzen Aguiñiga-Sánchez, Víctor Manuel Mendoza-Núñez, Jorge Cadena-Iñiguez, Ernesto Romero-López and Edelmiro Santiago-Osorio
Int. J. Mol. Sci. 2024, 25(21), 11477; https://doi.org/10.3390/ijms252111477 - 25 Oct 2024
Viewed by 1457
Abstract
There are hereditary mutations that predispose individuals to cancer development, such as pathogenic variants in the germ line of the tumor protein 53 (TP53) suppressor gene. This leads to a rare condition known as Li–Fraumeni syndrome (LFS), characterized by a high [...] Read more.
There are hereditary mutations that predispose individuals to cancer development, such as pathogenic variants in the germ line of the tumor protein 53 (TP53) suppressor gene. This leads to a rare condition known as Li–Fraumeni syndrome (LFS), characterized by a high risk of developing multiple cancers throughout life by the precancerous niche that promotes the tumor microenvironment. LFS presents a significant challenge due to its limited therapeutic and chemoprophylactic options. Recently, protocols involving metformin as a prophylactic medication have been developed to target precancerous niches. However, this approach is still in the clinical phase, and no established therapeutic regimen is available. Therefore, new alternatives are needed to impact this disease effectively. Novel studies suggest that Sechium extract, rich in polyphenols, exhibits chemoprophylactic, antineoplastic, anti-inflammatory, and antioxidant activities, all involved in the tumor microenvironment of LFS. However, the specific role of Sechium extract in preventing recurrent neoplastic development in LFS remains unclear. We conducted this research through a case report of an LFS-diagnosed patient who has experienced multiple malignancies and cutaneous neoformations. This patient received a chemoprophylactic supplementation based on Sechium H387 07 extract over 11 years without reporting new primary malignancy events or recurrences, as evidenced by laboratory and positron emission tomography/computed tomography (PET/CT) studies. An extensive literature review on the disease, precancerous niche, tumor microenvironment, and potential mechanisms of Sechium H387 07 extract components was conducted to explain cancer absence in LFS. This review promotes the research and use of polyphenols as powerful chemoprophylactic agents to prevent and treat proliferative diseases like LFS. Full article
(This article belongs to the Special Issue Advances in Cancer Chemoprevention and Therapeutics)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop